Drug facts
MoleculeOctreotide (Sandostatin)
Generics already compete: 9 makers on the market. 38 A-rated products from 9 makers substitute at the counter.
Sandostatin was first approved by the FDA on 10/21/1988 under NDA 019667; the application holder is Novartis Pharmaceuticals Corp.
The latest NADAC for OCTREOTIDE ACET 50 MCG/ML VIAL is $2.64 per mL (as of 10/28/2026).
Holder Novartis Pharmaceuticals CorpApplication NDA 019667Approved 10/21/1988
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Sandostatin patent listed in the Orange Book Orange Book
- Later patents, other products
- Bynfezia Pen 12/29/2041; Mycapssa 12/28/2040 Orange Book
02Competition
- Generics
- 9 generic makers Orange Book
- First generic approved
- 03/28/2005 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Octreotide profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $2.64 per mLOCTREOTIDE ACET 50 MCG/ML VIAL, as of 10/28/2026 CMS NADAC
- Latest recall
- 04/24/2026Class II, Octreotide Acetate, Teva Pharmaceuticals USA, Inc FDA enforcement
04Product
- Application holder
- Novartis Pharmaceuticals Corp Orange Book
- Application
- NDA 019667 Orange Book
- First approved
- 10/21/1988 Orange Book
- Dosage forms
- capsule, delayed release; injectable; solution
- Routes
- injection, oral, subcutaneous
- Other brand names
- Bynfezia PenMycapssaSandostatin Lar
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.